{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:17:31Z","timestamp":1791389851280,"version":"4.3.3"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020206","name":"Shandong Province Hygiene Department","doi-asserted-by":"publisher","award":["MR20241828"],"award-info":[{"award-number":["MR20241828"]}],"id":[{"id":"10.13039\/501100020206","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.lungcan.2025.108641","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:35:33Z","timestamp":1751373333000},"page":"108641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Advances in the treatment of brain metastases in EGFR-mutant non-small cell lung cancer"],"prefix":"10.1016","volume":"206","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8531-7526","authenticated-orcid":false,"given":"Haoxin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiran","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongkai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiurong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108641_b0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2025.108641_b0010","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","article-title":"Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: a Systematic Review and Meta-Analysis","volume":"18","author":"Gillespie","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11060-017-2590-x","article-title":"High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases","volume":"135","author":"Ge","year":"2017","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.lungcan.2025.108641_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102664","article-title":"The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer","volume":"122","author":"Ciardiello","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2025.108641_b0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer","volume":"18","author":"Su","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0030","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.lungcan.2025.108641_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112190","article-title":"Cancer driver gene and non-coding RNA alterations as biomarkers of brain metastasis in lung cancer: a review of the literature","volume":"143","author":"Karimpour","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lungcan.2025.108641_b0040","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/ATVBAHA.111.223537","article-title":"Consequences of epidermal growth factor receptor (ErbB1) loss for vascular smooth muscle cells from mice with targeted deletion of ErbB1","volume":"31","author":"Schreier","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.lungcan.2025.108641_b0045","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lungcan.2025.108641_b0050","doi-asserted-by":"crossref","DOI":"10.1177\/1533033820977546","article-title":"microRNA-195 promotes small cell lung cancer cell apoptosis via inhibiting Rap2C protein-dependent MAPK signal transduction","volume":"19","author":"Tong","year":"2020","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.lungcan.2025.108641_b0055","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/cgt.2012.91","article-title":"RNA interference targeting human FAK and EGFR suppresses human non-small-cell lung cancer xenograft growth in nude mice","volume":"20","author":"Li","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.lungcan.2025.108641_b0060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.gene.2017.11.029","article-title":"EGFR and Ras regulate DDX59 during lung cancer development","volume":"642","author":"Yang","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.lungcan.2025.108641_b0065","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nrm3904","article-title":"Remodelling the extracellular matrix in development and disease","volume":"15","author":"Bonnans","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.lungcan.2025.108641_b0070","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/s41580-024-00767-3","article-title":"Mechanisms of assembly and remodelling of the extracellular matrix","volume":"25","author":"Naba","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.lungcan.2025.108641_b0075","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1074\/mcp.M900381-MCP200","article-title":"Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes","volume":"9","author":"Park","year":"2010","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.lungcan.2025.108641_b0080","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1074\/jbc.M112.417451","article-title":"Matrix metalloproteinase-1-mediated up-regulation of vascular endothelial growth factor-2 in endothelial cells","volume":"288","author":"Mazor","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lungcan.2025.108641_b0085","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc3647","article-title":"Beyond E-cadherin: roles of other cadherin superfamily members in cancer","volume":"14","author":"Van Roy","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lungcan.2025.108641_b0090","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/0008-5472.CAN-06-2808","article-title":"Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells","volume":"67","author":"Symowicz","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108641_b0095","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/onc.2012.563","article-title":"Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K\/Akt\/mTOR signaling","volume":"33","author":"Brouxhon","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2025.108641_b0100","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial-mesenchymal transition","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.lungcan.2025.108641_b0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.lungcan.2025.108641_b0110","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","article-title":"The epithelial-mesenchymal transition generates cells with properties of stem cells","volume":"133","author":"Mani","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2025.108641_b0115","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2025.108641_b0120","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1158\/0008-5472.CAN-16-0176","article-title":"Snail1-dependent activation of cancer-associated fibroblast controls epithelial tumor cell invasion and metastasis","volume":"76","author":"Alba-Castell\u00f3n","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108641_b0125","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/nar\/gkx958","article-title":"Snail1 transcription factor controls telomere transcription and integrity","volume":"46","author":"Mazzolini","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.lungcan.2025.108641_b0130","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41392-024-01938-6","article-title":"Circulating tumor cells: from new biological insights to clinical practice","volume":"9","author":"Gu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.lungcan.2025.108641_b0135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41568-019-0221-x","article-title":"Fluids and their mechanics in tumour transit: shaping metastasis","volume":"20","author":"Follain","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lungcan.2025.108641_b0140","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41392-023-01725-9","article-title":"New insights into the correlations between circulating tumor cells and target organ metastasis","volume":"8","author":"Zhan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.lungcan.2025.108641_b0145","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc3004","article-title":"Contribution of platelets to tumour metastasis","volume":"11","author":"Gay","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lungcan.2025.108641_b0150","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1158\/0008-5472.CAN-09-2123","article-title":"Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity","volume":"69","author":"Kopp","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108641_b0155","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","article-title":"Emerging Biological Principles of Metastasis","volume":"168","author":"Lambert","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2025.108641_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188770","article-title":"Platelet cancer cell interplay as a new therapeutic target","volume":"1877","author":"Morris","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.lungcan.2025.108641_b0165","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by TGF-beta: \u201cN1\u201d versus \u201cN2\u201d TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2025.108641_b0170","doi-asserted-by":"crossref","first-page":"28418","DOI":"10.18632\/oncotarget.16084","article-title":"Circulating tumor cells promote the metastatic colonization of disseminated carcinoma cells by inducing systemic inflammation","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2025.108641_b0175","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nm.2753","article-title":"Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET","volume":"18","author":"Peinado","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2025.108641_b0180","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1182\/blood-2014-12-618025","article-title":"Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts","volume":"126","author":"Paggetti","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.lungcan.2025.108641_b0185","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-016-0269-y","article-title":"Lung tumor exosomes induce a pro-inflammatory phenotype in mesenchymal stem cells via NF\u03baB-TLR signaling pathway","volume":"9","author":"Li","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0190","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12026-018-9000-0","article-title":"Role of T cell-derived exosomes in immunoregulation","volume":"66","author":"Lu","year":"2018","journal-title":"Immunol. Res."},{"key":"10.1016\/j.lungcan.2025.108641_b0195","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/s41388-020-1182-y","article-title":"EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells","volume":"39","author":"Yu","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2025.108641_b0200","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1096\/fj.201601138RR","article-title":"Desmoglein 2 modulates extracellular vesicle release from squamous cell carcinoma keratinocytes","volume":"31","author":"Overmiller","year":"2017","journal-title":"FASEB J."},{"key":"10.1016\/j.lungcan.2025.108641_b0205","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fncel.2018.00235","article-title":"Microglia\/astrocytes-glioblastoma crosstalk: crucial molecular mechanisms and microenvironmental factors","volume":"12","author":"Matias","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.lungcan.2025.108641_b0210","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/2159-8290.CD-21-0910","article-title":"Targeting S100A9-ALDH1A1-retinoic acid signaling to suppress brain relapse in EGFR-mutant lung cancer","volume":"12","author":"Biswas","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2025.108641_b0215","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.molmed.2015.04.001","article-title":"EGFR and NF-\u03baB: partners in cancer","volume":"21","author":"Shostak","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.lungcan.2025.108641_b0220","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1021\/acs.jmedchem.6b01774","article-title":"First bispecific inhibitors of the epidermal growth factor receptor kinase and the NF-\u03baB activity as novel anticancer agents","volume":"60","author":"Hamed","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lungcan.2025.108641_b0225","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1158\/0008-5472.CAN-15-0989","article-title":"Ligand-independent EGFR signaling","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108641_b0230","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.7150\/thno.69682","article-title":"Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy","volume":"12","author":"Upton","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.lungcan.2025.108641_b0235","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/neuonc\/not222","article-title":"Functional role of endothelial adhesion molecules in the early stages of brain metastasis","volume":"16","author":"Soto","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0240","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6107456","article-title":"Chemotherapeutic stress induces transdifferentiation of glioblastoma cells to endothelial cells and promotes vascular mimicry","volume":"2019","author":"Baisiwala","year":"2019","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.lungcan.2025.108641_b0245","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061622","article-title":"Cellular plasticity and tumor microenvironment in gliomas: the struggle to hit a moving target","author":"Gargini","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2025.108641_b0250","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s43556-025-00251-0","article-title":"Cancer brain metastasis: molecular mechanisms and therapeutic strategies","volume":"6","author":"Lu","year":"2025","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.lungcan.2025.108641_b0255","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41571-021-00529-6","article-title":"The blood-tumour barrier in cancer biology and therapy","volume":"18","author":"Steeg","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0260","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1182\/blood.2019000633","article-title":"R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-\u03b1 in primary CNS lymphoma","volume":"134","author":"Ferreri","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.lungcan.2025.108641_b0265","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtho.2024.03.016","article-title":"Unveiling the landscape of uncommon EGFR mutations in NSCLC-A systematic review","volume":"19","author":"Borgeaud","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0270","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA Trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0275","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.23.02219","article-title":"CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor-mutated advanced non-small-cell lung cancer","volume":"42","author":"J\u00e4nne","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0280","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.24.00708","article-title":"Phase II efficacy and safety of 80 mg osimertinib in patients with leptomeningeal metastases associated with epidermal growth factor receptor mutation-positive non-small cell lung Cancer (BLOSSOM)","volume":"42","author":"Park","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0285","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.24.00533","article-title":"A Multicenter open-label randomized phase II study of osimertinib with and without ramucirumab in tyrosine kinase inhibitor-na\u00efve EGFR-mutant metastatic non-small cell lung cancer (RAMOSE trial)","volume":"43","author":"Le","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0290","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.annonc.2024.08.2243","article-title":"Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study","volume":"35","author":"Lu","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0295","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1021\/acsmedchemlett.2c00213","article-title":"Structural basis for inhibition of mutant EGFR with lazertinib (YH25448)","volume":"13","author":"Heppner","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.lungcan.2025.108641_b0300","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1158\/1078-0432.CCR-18-2906","article-title":"YH25448, an irreversible EGFR-TKI with potent intracranial activity in EGFR mutant non-small cell lung cancer","volume":"25","author":"Yun","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108641_b0305","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.omto.2022.02.006","article-title":"Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, invivo, and exvivo","volume":"24","author":"Fan","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.lungcan.2025.108641_b0310","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1200\/JCO.23.00515","article-title":"Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: results from LASER301","volume":"41","author":"Cho","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0315","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.jtho.2023.08.017","article-title":"Central nervous system outcomes of lazertinib versus gefitinib in EGFR-mutated advanced NSCLC: a LASER301 subset analysis","volume":"18","author":"Soo","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0320","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaoncol.2024.2640","article-title":"Lazertinib in EGFR-variant non-small cell lung cancer with CNS failure to prior EGFR tyrosine kinase inhibitors: a nonrandomized controlled trial","volume":"10","author":"Hong","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0325","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jtho.2021.11.025","article-title":"A phase 1\/2 study of lazertinib 240 mg in patients with advanced EGFR T790M-positive NSCLC after previous EGFR tyrosine kinase inhibitors","volume":"17","author":"Cho","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0330","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2025.108641_b0335","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","article-title":"Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications","volume":"24","author":"Cho","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108641_b0340","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","article-title":"Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR Exon 20 insertion-driven NSCLC","volume":"10","author":"Yun","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2025.108641_b0345","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus Lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108641_b0350","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.annonc.2024.05.541","article-title":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA","volume":"35","author":"Felip","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0355","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0360","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.21.01323","article-title":"Poziotinib in non-small-cell lung cancer harboring HER2 Exon 20 insertion mutations after prior therapies: ZENITH20-2 Trial","volume":"40","author":"Le","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0365","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1200\/JCO.23.00152","article-title":"Safety, tolerability, and antitumor activity of zipalertinib among patients with non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions","volume":"41","author":"Piotrowska","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0370","article-title":"First-line mobocertinib versus platinum-based chemotherapy in patients with EGFR Exon 20 insertion-positive metastatic non-small cell lung cancer in the phase III EXCLAIM-2 Trial","volume":"Jco2401269","author":"J\u00e4nne","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0375","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S2213-2600(23)00379-X","article-title":"Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial","volume":"12","author":"Wang","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2025.108641_b0380","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I Study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0385","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108641_b0390","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jtho.2019.12.126","article-title":"Afatinib for the treatment of NSCLC harboring uncommon EGFR MUTATIONS: A DATABASE OF 693 Cases","volume":"15","author":"Yang","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0395","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0400","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jtho.2024.09.1385","article-title":"High-dose furmonertinib in patients with EGFR-mutated NSCLC and leptomeningeal metastases: a prospective real-world study","volume":"20","author":"Chen","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0405","doi-asserted-by":"crossref","unstructured":"S.S. Zhang, S.I. Ou, Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, uncommon-G719X, S768I, L861Q\u201c) Among the Third-Generation EGFR TKIs? Lung Cancer (Auckl) 2022; 13: 67-73. doi: 10.2147\/lctt.S385437.","DOI":"10.2147\/LCTT.S385437"},{"key":"10.1016\/j.lungcan.2025.108641_b0410","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamaoncol.2023.5013","article-title":"First-Line Osimertinib for previously untreated patients with NSCLC and uncommon EGFR mutations: the UNICORN phase 2 nonrandomized clinical trial","volume":"10","author":"Okuma","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0415","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S2213-2600(23)00183-2","article-title":"Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2025.108641_b0420","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S2213-2600(17)30378-8","article-title":"Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study","volume":"5","author":"Ahn","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2025.108641_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.09.002","article-title":"First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: the phase 3 EVEREST trial","volume":"6","author":"Zhou","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.lungcan.2025.108641_b0430","article-title":"Safety, Pharmacokinetics, and efficacy of asandeutertinib in advanced EGFR-mutated NSCLC: a phase 1 dose-escalation and dose-expansion study","author":"Han","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104288","article-title":"Efficacy of PD-1\/PD-L1 immunotherapy on brain metastatic non-small-cell lung cancer and treatment-related adverse events: a systematic review","volume":"196","author":"Phillips","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.lungcan.2025.108641_b0440","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108641_b0445","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2025.108641_b0450","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108641_b0455","article-title":"Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2025.108641_b0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2018.01.005","article-title":"Interactions between EGFR and PD-1\/PD-L1 pathway: Implications for treatment of NSCLC","volume":"418","author":"Li","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.lungcan.2025.108641_b0465","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jtho.2022.01.012","article-title":"Osimertinib plus durvalumab in patients with EGFR-mutated, advanced NSCLC: a phase 1b, Open-Label","volume":"17","author":"Ahn","year":"2022","journal-title":"Multicenter Trial. J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2025.108641_b0470","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1200\/JCO.23.02747","article-title":"Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor\u2013resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer","volume":"42","author":"Yang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0475","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.23.01017","article-title":"Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722","volume":"42","author":"Mok","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0480","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1200\/JCO.23.01891","article-title":"Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04)","volume":"42","author":"Park","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0485","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial","volume":"332","author":"Fang","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2025.108641_b0490","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S1470-2045(24)00379-6","article-title":"Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis","volume":"25","author":"Zhao","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0495","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(24)00573-4","article-title":"Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial","volume":"26","author":"Heinzerling","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0500","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S1470-2045(24)00643-0","article-title":"Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial","volume":"26","author":"Xu","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0505","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.21037\/tlcr-20-552","article-title":"Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents","volume":"10","author":"Wrona","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.lungcan.2025.108641_b0510","first-page":"412","article-title":"Thoracic radiotherapy improves the survival in patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors: a multicenter, randomized, controlled","volume":"43","author":"Sun","year":"2025","journal-title":"Phase III Trial. J Clin Oncol"},{"key":"10.1016\/j.lungcan.2025.108641_b0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110334","article-title":"Stereotactic radiotherapy vs whole brain radiation therapy in EGFR mutated NSCLC: results & reflections from the prematurely closed phase III HYBRID trial","volume":"197","author":"Zeng","year":"2024","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102853","article-title":"Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial","volume":"76","author":"Zhou","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.lungcan.2025.108641_b0525","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.21037\/tlcr-24-414","article-title":"Narrative review of stereotactic body radiation therapy combined with tyrosine kinase inhibitors for oligometastatic EGFR-mutated non-small cell lung cancer: present and future developments","volume":"13","author":"Zhao","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108641_b0530","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40265-018-0916-4","article-title":"Targeting EGFR in lung cancer: current standards and developments","volume":"78","author":"D\u00edaz-Serrano","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.lungcan.2025.108641_b0535","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0540","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1007\/s00432-020-03239-1","article-title":"Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes","volume":"146","author":"Mu","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0545","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13045-019-0759-9","article-title":"MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer","volume":"12","author":"Wang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0550","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1200\/JCO.18.01585","article-title":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","volume":"37","author":"Marcoux","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0555","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0560","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lungcan.2025.108641_b0565","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41698-022-00338-9","article-title":"Antibody-drug conjugates in lung cancer: dawn of a new era?","volume":"7","author":"Coleman","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0570","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 Trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0575","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/S1470-2045(24)00261-4","article-title":"CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer","volume":"25","author":"Lazaratos","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0580","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0585","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.annonc.2024.02.003","article-title":"Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC","volume":"35","author":"Yu","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0590","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 Study","volume":"43","author":"Ahn","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0595","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 Study","volume":"43","author":"Sands","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.01.001","article-title":"Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib","author":"Horinouchi","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0605","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jtho.2024.07.008","article-title":"Longitudinal analyses of circulating tumor DNA for the detection of EGFR mutation-positive advanced NSCLC progression during treatment: data from FLAURA and AURA3","volume":"19","author":"Gray","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0610","article-title":"Tumor DNA mutations from intraparenchymal brain metastases are detectable in CSF","volume":"5","author":"Cheok","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0615","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/1878-0261.13357","article-title":"Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC","volume":"17","author":"Wu","year":"2023","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.lungcan.2025.108641_b0620","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11060-024-04695-2","article-title":"Establishing the utility of multi-platform liquid biopsy by integrating the CSF methylome and proteome in CNS tumours","volume":"169","author":"Landry","year":"2024","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.lungcan.2025.108641_b0625","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11060-023-04487-0","article-title":"Rapid detection of mutations in CSF-cfTNA with the genexus integrated sequencer","volume":"166","author":"Arjuna","year":"2024","journal-title":"J. Neurooncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225005331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225005331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:30:03Z","timestamp":1778473803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225005331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":125,"alternative-id":["S0169500225005331"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108641","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the treatment of brain metastases in EGFR-mutant non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108641"}}